"Over the past decade, as the price of cancer drugs has skyrocketed, many in the oncology community have asked this question: Is it possible to create a public policy that will harness these costs and cut out-of-pocket expenses for patients?"...
The possibility of overdosage with floxuridine is unlikely in view of the mode of administration. Nevertheless, the anticipated manifestations would be nausea, vomiting, diarrhea, gastrointestinal ulceration and bleeding, bone marrow depression (including thrombocytopenia, leukopenia and agranulocytosis). No specific antidotal therapy exists. Patients who have been exposed to an overdosage of floxuridine should be monitored hematologically for at least 4 weeks. Should abnormalities appear, appropriate therapy should be utilized. The acute intravenous toxicity of floxuridine is as follows:
|Species||LD50 (mg/kg ± S.E.)|
|Mouse||880 ± 51|
|Rat||670 ± 73|
|Rabbit||94 ± 19.6|
|Dog||157 ± 46|
Floxuridine therapy is contraindicated for patients in a poor nutritional state, those with depressed bone marrow function or those with potentially serious infections.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/29/2016
Additional Floxuridine Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.